Physician profile
Richard Gestring
NPI 1043530728
$2,319.30
in general payments reported to CMS, 2019-2025
20 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $384 · 2021: $289 · 2022: $102 · 2023: $122 · 2024: $157 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $564.81 | 2019-2025 | Lybalvi |
| Sunovion Pharmaceuticals INC. | $358.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $287.36 | 2019-2024 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $164.70 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $140.97 | 2019-2020 | |
| Lundbeck LLC | $109.33 | 2019-2020 | |
| Allergan, INC. | $95.68 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $94.02 | 2019-2020 | |
| Neuronetics, INC. | $93.17 | 2019-2025 | Neurostar Tms Therapy System |
| Neos Therapeutics, LP | $92.77 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $86.86 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $63.33 | 2019 | |
| Abbvie INC. | $31.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.01 | 2019 | |
| Mdd US Operations, LLC | $23.09 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $19.98 | 2019 | |
| Indivior INC. | $19.57 | 2020 | |
| Harmony Biosciences LLC | $18.98 | 2024 | |
| Gilead Sciences, INC. | $14.04 | 2019 | |
| Adlon Therapeutics L.P. | $13.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gestring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.